<DOC>
	<DOCNO>NCT01500694</DOCNO>
	<brief_summary>For subject Europe already participate either Study SPD503-315 SPD503-316 . This extension study allow participant access Extended-release Guanfacine Hydrochloride ( HCl ) 2 year . This study help sponsor evaluate long-term safety tolerability Extended-release Guanfacine HCl ( SPD503 ) .</brief_summary>
	<brief_title>Access Extended Release Guanfacine HCl Subjects Who Participated Studies SPD503-315 SPD503-316 Europe</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>1 . Subjects Study SPD503318 available time final visit antecedent study ( SPD503315 SPD503316 ) , may still screen unless wellcontrolled another ADHD medication acceptable tolerability parent/caregiver satisfy current ADHD medication . 2 . Subject satisfied entry criterion antecedent study ( SPD503 315 SPD503316 ) . 3 . Subject female childbearing potential ( FOCP ) , define &gt; 9 year age &lt; 9 year age postmenarchal , must negative serum beta human chorionic gonadotropin ( hCG ) pregnancy test Screening Visit ( Visit 1 ) negative urine pregnancy test Baseline Visit ( Visit 2 ) agree comply applicable contraceptive requirement protocol . 4 . Subject 's parent legally authorise representative ( LAR ) must provide signature informed consent , must documentation assent ( applicable ) subject indicate subject aware investigational nature study require procedure restriction accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guideline E6 applicable regulation , complete studyrelated procedure . 5 . Subject parent/LAR willing , able , likely fully comply test requirement define protocol , include oversight dosing . Specifically , parent/LAR must available upon awaken , dispense dose investigational product duration study . 6 . Subject supine stand blood pressure ( BP ) measurement within 95th percentile age , sex , height . 7 . Subject function ageappropriate level intellectually , deem Investigator . 8 . Subject able swallow intact tablet . 1 . Subject current , control ( require prohibit medication behavioural modification program ) uncontrolled , comorbid psychiatric diagnosis ( except oppositional defiant disorder ) , include severe comorbid Axis II disorder severe Axis I disorder post traumatic stress disorder , bipolar illness , psychosis , pervasive developmental disorder , obsessivecompulsive disorder , substance abuse disorder , symptomatic manifestation lifetime history bipolar illness , psychosis conduct disorder , opinion Investigator , contraindicate treatment SPD503 confound efficacy safety assessment . The Kiddie Schedule Affective Disorders Schizophrenia Present Lifetime version ( KSADSPL ) rating antecedent study review confirm diagnosis , necessary . 2 . Subject early terminate Study SPD503315 Study SPD503316 protocol nonadherence , subject noncompliance , AE , SAE , withdrawal subject . 3 . Subject experience clinically significant AE prior SPD503 study ( SPD503315 SPD503 316 ) , opinion Investigator , would preclude exposure SPD503 . 4 . Clinically important abnormality urine drug and/or alcohol screen Screening Visit ( Visit 1 ) . 5 . Subject take investigational product follow : last dose investigational product Study SPD503315 within 7 day prior Baseline Visit ( Visit 2 ) ; investigational product Study SPD503 316 within 30 day prior Baseline Visit ( Visit 2 ) ; investigational product within 30 day prior Baseline Visit ( Visit 2 ) ADHD medication within 30 day prior Baseline Visit ( Visit 2 ) . 6 . Subject significantly overweight base Center Disease Control Prevention Body Mass Index ( BMI ) forage sexspecific chart Screening Visit ( Visit 1 ) . Significantly overweight define BMI &gt; 95th percentile . 7 . Children age 6 12 year body weight less 25.0kg adolescent age 13 year old body weight less 34.0kg Screening Visit ( Visit 1 ) . 8 . Subject condition illness include clinically significant abnormal laboratory value Screening Visit ( Visit 1 ) , opinion Investigator , represent inappropriate risk subject and/or could confound interpretation study . 9 . Subject currently consider suicide risk opinion Investigator , previously make suicide attempt , prior history , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment Investigator . 10 . Subject clinically significant ECG finding , judge Investigator consideration central ECG laboratory 's interpretation , Baseline Visit ( Visit 2 ) . 11 . Subject know suspected allergy , hypersensitivity , clinically significant intolerance guanfacine hydrochloride , component find SPD503 . 12 . Subject history alcohol substance abuse dependence , define Diagnostic Statistical Manual Mental Disorders , Fourth EditionText RevisionÒ ( DSMIVTRÒ ; exception nicotine ) within last 6 month . 13 . Subject history seizure disorder ( single childhood febrile seizure occur age 3 year ) presence serious tic disorder include Tourette 's syndrome . 14 . Subject known history presence structural cardiac abnormality , serious heart rhythm abnormality , syncope , cardiac conduction problem ( eg , clinically significant heart block ) , exercise related cardiac event include syncope pre syncope , clinically significant bradycardia . 15 . Subject orthostatic hypotension know history control uncontrolled hypertension . 16 . Current use prohibit medication medication , include herbal supplement , affect BP heart rate central nervous system ( CNS ) effect affect cognitive performance , sedate antihistamine decongestant sympathomimetics ( inhaled bronchodilator permit ) history chronic use sedate medication ( ie , antihistamine ) violation protocol specify washout criterion Baseline Visit ( Visit 2 ) . 17 . Subject medical condition , ADHD , require treatment medication CNS effect and/or affect performance . 18 . Subject female pregnant currently lactate . 19 . Subject fail screen previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>